MGMT and central nervous system cancer: The beneficial effect of MGMT promoter methylation and gene inactivation is corroborated by Glioma-BioDP in Fig. 3e, f, showing that decreased MGMT protein expression is associated with longer survival times in the clinical setting as the tumor progresses (p-value; 0.309 in LGG vs p-value: 0.042 in GBM, below and above median analysis).